Method to slow ventricular rate
AssigneeInCarda Therapeutics, Inc.
InventorsLuiz Belardinelli, Rangachari Narasimhan, Carlos Schuler
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, formulations, and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using selective β1 adrenergic receptor blockers. Also disclosed herein are methods, formulations, and kits for treating a heart condition via inhalation or intranasal spray administration of selective β1 adrenergic receptor blocker and class I antiarrhythmic agent.
Claims30
A method of treating a subject suffering from atrial arrhythmia, comprising administering to said subject via inhalation:
- (i) a therapeutically effective amount of a β1-selective adrenergic receptor blocker;
- and
- (ii) a therapeutically effective amount of a class I antiarrhythmic agent,
- wherein said therapeutically effective amount of said β1-selective adrenergic receptor blocker and said therapeutically effective amount of said class I antiarrhythmic agent, when both are administered via inhalation to an experimental subject suffering from said atrial arrhythmia in a clinical study, induce a faster cardioversion of said atrial arrhythmia in said experimental subject as compared to:
- (a) administering said therapeutically effective amount of said β1-selective adrenergic receptor blocker via inhalation to a control subject suffering from said atrial arrhythmia in said clinical study without a class I antiarrhythmic agent;
- or
- (b) administering said therapeutically effective amount of said class I antiarrhythmic agent via inhalation to a control subject suffering from said atrial arrhythmia in said clinical study without a β1-selective adrenergic receptor blocker;
- and
- wherein said inhalation administration of both said therapeutically effective amount of said β1-selective adrenergic receptor blocker and said therapeutically effective amount of said class I antiarrhythmic agent slows atrioventricular node conduction during said cardioversion.
A method of treating a patient suffering from atrial arrhythmia, comprising administering to said patient via inhalation:
- (i) a therapeutically effective amount of a β1-selective adrenergic receptor blocker;
- and
- (ii) a therapeutically effective amount of a class I antiarrhythmic agent,
- wherein said therapeutically effective amount of said β1-selective adrenergic receptor blocker and said therapeutically effective amount of said class I antiarrhythmic agent, when both are administered via inhalation to an experimental subject suffering from said atrial arrhythmia in a clinical study, induce cardioversion in said experimental subject and induce a greater reduction in average ventricular rate during said cardioversion in said experimental subject as compared to:
- (a) administering said therapeutically effective amount of said β1-selective adrenergic receptor blocker via inhalation to a control subject suffering from said atrial arrhythmia in said clinical study without a class I antiarrhythmic agent;
- or
- (b) administering said therapeutically effective amount of said class I antiarrhythmic agent via inhalation to a control subject suffering from said atrial arrhythmia in said clinical study without a β1-selective adrenergic receptor blocker;
- and
- wherein said inhalation administration of both said therapeutically effective amount of said β1-selective adrenergic receptor blocker and said therapeutically effective amount of said class I antiarrhythmic agent slows atrioventricular node conduction during said cardioversion.
Dependencies are inferred from the claim text.